What 3rd Shot “Boosters” of mRNA Vaccines do for Immune Responses and Clinical Effect
BNT162b2 Booster Increases Antibody Titers Against Delta Variant

Source: Falsay et al. *NEJM* 9/15/2021
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
YM Bar-On, A Huppert et al.

- Data for period 7/30 – 8/31, 2021 from 1.14 million people aged 60 years and older who had received a 2nd dose of mRNA vaccine at least 5 months earlier

- 12 days or more after the booster dose, the rate of confirmed infection was lower in the booster group than in the non-booster group by a factor of 11.3; the rate of severe illness was lower by a factor of 19.5
Reduction in Rate of Confirmed Infection in Booster Group as Compared with Nonbooster Group

Active Severe COVID-19 Cases by Vaccination Status, Age 60+ Years, Israel (per 100K Population)

Self-reported and Physiological Reactions to the Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose

M Mofaz, E Shmueli et al.

- N=1,609 individuals in Israel; prospective observational study

- Local and systemic reactions reported following the third (booster) dose were similar to those reported following the second dose and considerably greater than those reported following the first dose
Get Vaccinated!

After Delta became the most common variant, fully vaccinated people had reduced risk of:

- Infection: 5X
- Hospitalization: >10X
- Death: >10X

Vaccination offers strong protection against COVID-19


* June 30-July 17, 2021
† Compared with people not fully vaccinated